...Yes, so tariffs kind of in the same basket where we start with executive orders. I mean, at a high level we're really talking about here are the component parts that lead to our drug product that's available for commercial sale, not the actual commercial product itself, and we have redundant supply chains across the US and Western Europe for both. INGREZZA and for CRENESSITY, ultimately when we look at the component parts here, they add up to a very low cost of goods medicine with high gross margins, and we don't see tariffs playing a very significant role at all in terms of how they might affect our business. So, I think we are in pretty good shape there. Unidentified Participant Okay. And then lastly, your interactions with FDA to the extent that you've had recent ones, let's say over the last eight weeks or so, have you noticed anything in terms of the same people or timelines, extending or any kind of data point you can share?...
